- Clinical Trials
Webinar series will feature a weekly company overview highlighting the Genprex’s gene therapy pipeline in cancer and diabetes
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes
Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).
Company overview to highlight novel gene therapies for cancer and diabetes
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib
Investor presentation to highlight novel gene therapies for cancer and diabetes
Investor presentations to highlight novel gene therapies for cancer and diabetes
Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.
World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer
Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide